MARKET

PHIOW

PHIOW

PHIO PHARMACTCL
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.2400
+0.0003
+0.13%
Closed 16:00 05/18 EDT
OPEN
0.2400
PREV CLOSE
0.2397
HIGH
0.2401
LOW
0.2101
VOLUME
10.92K
TURNOVER
--
52 WEEK HIGH
1.160
52 WEEK LOW
0.0413
MARKET CAP
--
P/E (TTM)
-0.0965
1D
5D
1M
3M
1Y
5Y
BRIEF-Phio Pharmaceuticals Corp Files For Mixed Shelf Of Up To $100 Mln– SEC Filing
reuters.com · 5d ago
BRIEF-Phio Pharmaceuticals Reports First Quarter 2021 Financial Results And Provides Business Update
reuters.com · 5d ago
Phio Pharma's PH-762 Shows Encouraging Antitumor Efficacy In Preclinical Studies
Phio Pharmaceuticals Corp (NASDAQ: PHIO) stock falls despite the company announcing positive new in vivo data showing that PH-762 significantly enhanced the antitumor efficacy of HER2-targeted CAR-T cells (HER2CART) in solid tumors. Compared to untreated, ...
Benzinga · 05/11 17:10
Phio Pharmaceuticals Presents Positive In Vivo Data at ASGCT Showing PH-762 Significantly Enhanced Antitumor Efficacy of HER2-Targeted CAR-T Cells
PR Newswire · 05/11 12:56
BRIEF-Phio Presents Positive Data At ASGCT Showing Ph-762 Enhanced Antitumor Efficacy Of CAR-T Cells
reuters.com · 05/11 12:35
Phio Pharmaceuticals Announces Upcoming Data Presentations at the ASGCT and ASCO Annual Meetings
PR Newswire · 04/29 12:30
Phio Pharma's Intasyl Platform Shows Promising Tumor Control Activity In Animal Studies
Phio Pharmaceuticals Corp (NASDAQ: PHIO) announced new preclinical data for the Intasyl platform in tumor settings. These data were presented today during the AACR Annual Meeting 2021. Data showed that local intratumoral (IT) delivery with the murine PD-1 ...
Benzinga · 04/12 11:33
Phio Pharmaceuticals Presents Positive In Vivo Data Showing Strong Tumor Control for the Intratumoral Delivery of INTASYL™ RNAi Targeting PD-1
Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced new in vivo data showing intrat...
PR Newswire · 04/10 12:30
More
Forecast
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PHIOW. Analyze the recent business situations of PHIO PHARMACTCL through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
EPS
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.42%
Pharmaceuticals & Medical Research
+0.07%
Key Executives
Chairman/Director
Robert Bitterman
President/Chief Executive Officer/Chief Operating Officer
Gerrit Dispersyn
Other
John Barrett
Director
Geert Cauwenbergh
Independent Director
H. Paul Dorman
Independent Director
Jonathan Freeman
Independent Director
Curtis Lockshin
No Data
About PHIOW
Phio Pharmaceuticals Corp, formerly RXi Pharmaceuticals Corporation, is a biotechnology company. The Company is focused on developing immuno-oncology therapeutics based on its self-delivering ribonucleic acid interface (RNAi) (sd-rxRNA) therapeutic platform. The Company’s focuses on developing sd-rxRNA therapeutic compounds to be used in the context of adoptive cell transfer by targeting checkpoints or other gene targets, or to be used in immunotherapy following intratumoral injection. The Company’s pipeline include RXI-762 and RXI-804. Its sd-rxRNA compounds are designed to down-regulate the expression of a specific gene that may be over-expressed in a disease condition. The Company is developing RXI-762 for the treatment of Melanoma, Ovarian cancer and other indications. RXI-804 is an sd-rxRNA compound that is designed to suppress the expression of immune checkpoint protein, TIGIT.

Webull offers kinds of Phio Pharmaceuticals Corp stock information, including NASDAQ:PHIOW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PHIOW stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PHIOW stock methods without spending real money on the virtual paper trading platform.